Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mauna Kea Technologies S.A. (ALMKT.PA)
EUR0.16
0.00 (-1.10%)
FR PAR Healthcare Medical - Devices
Address
9, rue d'Enghien 75010
Paris, FR
Paris, FR
CEO
Alexandre Loiseau
Website
maunakeatech.com
IPO
2023-07-31
ISIN FR0010609263
Also trades on
Euronext Paris · ALMKT.PA (EUR)
Euronext Paris · MKEA.PA (EUR)
Other OTC · MKEAF (USD)
Description
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR0.16
0.00 (-1.10%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
705.7K
Beta
0.96
Float Shares
60.11M
Free Float %
72.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | +0.00% | -3.26% | +7.10% | +123.06% | +143.50% | +102.27% | -71.61% | -71.61% | -71.61% | -71.61% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.16
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-04 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.68
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+7.4% Q4'25: +16.6% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+138.5% ★ Q4'25: +173.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-92.5% Q4'25: -36.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-83.3% Q4'25: -68.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-299.0% Q4'25: -539.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+149.6% Q4'25: +209.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.76× Q4'25: -0.98× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.79M
est.
|
6.69M
est.
|
6.76M
est.
|
8.51M
est: 7.43M (+14.5%)
|
6.53M
est: 6.53M (+0.0%)
|
7.70M
est: 7.70M (+0.0%)
|
7.48M
est: 7.48M (+0.0%)
|
11.03M
est: 8.15M (+35.2%)
|
7.66M
est: 7.64M (+0.2%)
|
8.22M
est: 7.99M (+2.9%)
|
7.75M
7.75M – 7.75M
-3.0% YoY
|
10.15M
10.15M – 10.15M
+31.0% YoY
|
13.00M
13.00M – 13.00M
+28.1% YoY
|
16.40M
16.40M – 16.40M
+26.2% YoY
|
19.40M
19.40M – 19.40M
+18.3% YoY
|
| EBITDA |
-7.26M
est.
|
-5.53M
est.
|
-5.59M
est.
|
-13.98M
est: -6.14M (-127.7%)
|
-11.43M
est: -5.39M (-111.9%)
|
-11.23M
est: -6.36M (-76.5%)
|
-9.93M
est: -6.18M (-60.7%)
|
-1.46M
est: -6.47M (+77.4%)
|
-7.97M
est: -6.06M (-31.5%)
|
-6.85M
est: -6.34M (-8.0%)
|
-6.15M
-6.15M – -6.15M
+3.0% YoY
|
-8.05M
-8.05M – -8.05M
-31.0% YoY
|
-10.31M
-10.31M – -10.31M
-28.1% YoY
|
-13.01M
-13.01M – -13.01M
-26.2% YoY
|
-15.38M
-15.38M – -15.38M
-18.3% YoY
|
| EBIT |
-7.51M
est.
|
-5.71M
est.
|
-5.77M
est.
|
-14.67M
est: -6.35M (-131.2%)
|
-12.74M
est: -5.57M (-128.6%)
|
-13.42M
est: -6.58M (-104.0%)
|
-10.93M
est: -6.39M (-71.0%)
|
-2.98M
est: -6.69M (+55.4%)
|
-9.95M
est: -6.27M (-58.7%)
|
-6.85M
est: -6.56M (-4.4%)
|
-6.36M
-6.36M – -6.36M
+3.0% YoY
|
-8.33M
-8.33M – -8.33M
-31.0% YoY
|
-10.67M
-10.67M – -10.67M
-28.1% YoY
|
-13.46M
-13.46M – -13.46M
-26.2% YoY
|
-15.92M
-15.92M – -15.92M
-18.3% YoY
|
| Net Income |
-38.90M
est.
|
-34.78M
est.
|
-34.34M
est.
|
-15.27M
est: -28.73M (+46.8%)
|
-12.79M
est: -29.48M (+56.6%)
|
-13.45M
est: -26.09M (+48.5%)
|
-11.18M
est: -7.89M (-41.7%)
|
-3.73M
|
-10.40M
est: -17.49M (+40.5%)
|
10.77M
est: 14.87M (-27.5%)
|
-1.75M
-1.75M – -1.75M
-111.8% YoY
|
-1.75M
-1.75M – -1.75M
+0.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
4.68M
est.
|
3.57M
est.
|
3.60M
est.
|
15.71M
est: 3.96M (+296.6%)
|
4.42M
est: 3.48M (+27.0%)
|
5.19M
est: 4.11M (+26.5%)
|
3.86M
est: 3.99M (-3.2%)
|
4.18M
est: 4.97M (-15.8%)
|
3.21M
est: 4.65M (-31.0%)
|
8.69M
est: 4.87M (+78.5%)
|
4.72M
4.72M – 4.72M
-3.0% YoY
|
6.18M
6.18M – 6.18M
+31.0% YoY
|
7.92M
7.92M – 7.92M
+28.1% YoY
|
9.99M
9.99M – 9.99M
+26.2% YoY
|
11.81M
11.81M – 11.81M
+18.3% YoY
|
| EPS |
-0.56
est.
|
-0.50
est.
|
-0.49
est.
|
-0.50
est: -0.41 (-22.0%)
|
-0.42
est: -0.42 (+0.2%)
|
-0.35
est: -0.37 (+6.0%)
|
-0.25
est: -0.11 (-122.0%)
|
-0.08
|
-0.16
est: -0.10 (-60.0%)
|
0.06
est: 0.09 (-27.5%)
|
-0.01
-0.01 – -0.01
-111.8% YoY
|
-0.01
-0.01 – -0.01
+0.0% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-10.82M
OE per share TTM
-0.16
Owner's Yield
-36.39%
Maintenance CapEx ratio
0.16%
Maint CapEx / Avg PPE
24.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-105.3K
Shares Outstanding
82.88M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexandre Loiseau | Co-Founder, Chief Executive Officer & Chairman | 172.6K | male |
| Come de La Tour du Pin | Chief Financial Officer | — | male |
| Daryl Donatelli | President of U.S. & Head of Global Marketing | — | male |
| François Lacombe | Chief Scientific Officer | — | male |
| Frederic Banegas | Chief Technology Officer | — | male |
| Nathalie Lecoq | Chief Operating Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALMKT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
